Delving into the Latest Updates on ImmuLogic Pharmaceutical Corp. with Synapse

概览

排名前五的药物类型	数量

治疗性疫苗	1

关联

1

项与 ImmuLogic Pharmaceutical Corp. 相关的药物

Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical)

靶点-

作用机制

免疫刺激剂

在研机构

Celtic Pharma GP Ltd. [+1]

原研机构

ImmuLogic Pharmaceutical Corp.

在研适应症

可卡因相关疾病

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

100 项与 ImmuLogic Pharmaceutical Corp. 相关的临床结果

登录后查看更多信息

0 项与 ImmuLogic Pharmaceutical Corp. 相关的专利（医药）

登录后查看更多信息

54

项与 ImmuLogic Pharmaceutical Corp. 相关的文献（医药）

1999-06-01·Journal of biomolecular techniques : JBT

Application of proteases to the identification of chiral modifications in synthetic peptides.

Article

作者: Keating, K M

Racemization of amino acids during solid-phase synthesis of peptides leads to the formation of side products that are chirally modified peptides. The chiral specificity of enzymes can be exploited to identify the sites of the modifications in these impurities. One such impurity, designated X5, was isolated from the target peptide, Fel-1, and demonstrated to be an optical isomer of Fel-1 by N-terminal sequencing and mass spectrometry. A chymotryptic digest was done on the isolated X5 and Fel-1. The fragments were separated on reversed-phase high-performance liquid chromatography (HPLC). Mass spectral data on the fragment from X5, with a different retention time from the analogous fragment of Fel-1, suggested that the modification was in the N-terminal portion of the peptide. Enzymatic digestion by Asp-N protease followed by HPLC of the fragments and mass spectral analysis provided evidence that an aspartic acid at position 5 was a D-amino acid in X5, because that position was not cleaved. These results contributed to the identification of X5 as an optical isomer of Fel-1, with a D-aspartic acid replacing an L-aspartic acid normally present at position 5.

1998-03-01·Biophysical chemistry4区 · 生物学

On the kinetics of peptide binding to MHC proteins

4区 · 生物学

Article

作者: Berezhkovskiy, L M

An experimental study of kinetics of peptide binding to MHC proteins [S. Witt, H. McConnell, Acc. Chem. Res. 26 (1993) 442 (and references therein)] showed an unusual phenomenon of the so-called 'negative' t1/2 plots (where t1/2 is half time of reaching equilibrium concentration of peptide-protein complexes), which is the shorter t1/2 at lower added peptide concentrations. The bell-shaped curve for t1/2 as a function of peptide concentration is a seemingly peculiar effect, because in general, binding reactions go faster with an increase of reagent concentrations. It is shown that the suggested explanation of this phenomenon [S. Witt, H. McConnell, Acc. Chem. Res. 26 (1993) 442 (and references therein)] is misleading (and the numerical simulation used to support this explanation is inconsistent with the experimental data), so that the existence of 'negative' t1/2 is in no way to be considered as an experimental indication of the two-step reaction of peptide binding to protein. This article gives a consistent explanation of the bell-shaped t1/2 plots for peptide-protein association and obtains the criteria for its existence, based exclusively on the formal chemical kinetics analysis of the accepted peptide-protein binding model and briefly discusses the experimental data, which really confirm the existence of the two-step mechanism of binding. The analysis of the maximum location of the half-time curves indicates a controversy between the prediction of the two-step binding model and the experimental data [S. Witt, H. McConnell, Acc. Chem. Res. 26 (1993) 442 (and references therein)]: either more complicated mechanism is involved in peptide-MHC binding or experimental data [S. Witt, H. McConnell, Acc. Chem. Res. 26 (1993) 442 (and references therein)] are not quite accurate.

1997-12-01·Drug and alcohol dependence2区 · 医学

Development of a therapeutic vaccine for the treatment of cocaine addiction

2区 · 医学

Article

作者: Fox, B S

No pharmacotherapies have yet been approved for the treatment of cocaine addiction. One new approach is to block the effects of cocaine with anti-cocaine antibodies induced by a therapeutic cocaine vaccine. A cocaine vaccine has been developed which induces a cocaine-specific antibody response in rodents. The antibody binds to cocaine in the circulation and can be shown to inhibit the ability of cocaine to enter the brain. Furthermore, anti-cocaine antibody can inhibit cocaine self-administration in rats. These data suggest that a cocaine vaccine may be a powerful therapeutic tool. The intent is to immunized motivated patients with the vaccine as part of a comprehensive treatment program. If the patient uses cocaine after being vaccinated, the antibody will inhibit the reinforcing activity of cocaine and decrease the likelihood of relapse.

1

项与 ImmuLogic Pharmaceutical Corp. 相关的新闻（医药）

2012-03-01

·BioSpace

Avaxia Biologics, Inc.'s Barbara Fox Named One of Mass High Tech's Women to Watch in 2012

LEXINGTON, Mass., March 1, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that Dr. Barbara Fox, its founder and CEO, has been was named one of Mass High Tech's Women to Watch in 2012. Mass High Tech's 9th annual Women to Watch awards recognize women in the fields of technology and life sciences, "who are go-getters, hardworking, inspirational and motivational to their peers." Dr. David Poorvin, member of the Board of Directors of Avaxia, commented, "We are truly proud of this recognition of Dr. Fox's achievements. She has been instrumental in building Avaxia Biologics from a creative idea into a developmental biotech company that will be testing its first drug candidate later this year. She is not only an innovative scientist, but also a motivational executive who leads by example. We are confident that she will continue to have a significant impact on drug development and the biotech communities in Massachusetts for years to come." Prior to founding Avaxia Biologics, Dr. Fox was the founder, President and Chief Scientific Officer of Recovery Pharmaceuticals, a company developing and marketing medications for the treatment of addiction. Prior to founding Recovery Pharmaceuticals in 1998, she was Vice President, Immunology at ImmuLogic Pharmaceutical Corp. She joined ImmuLogic in 1993, having served on the faculty of the University Maryland School of Medicine, Baltimore, as Associate Professor of Medicine with tenure in the Division of Rheumatology and Clinical Immunology, Dept. of Medicine. Dr. Fox received her BA in Chemistry from Bryn Mawr College and her Ph.D. in Chemistry from MIT. Dr. Fox trained as a post-doc in cellular immunology at the NIH. Mass High Tech will honor Dr. Fox and 19 other awardees at an awards breakfast on Friday, May 11, 2012 at the Fairmont Copley Plaza. About Avaxia Biologics, Inc.: Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity. SOURCE Avaxia Biologics, Inc.

抗体

100 项与 ImmuLogic Pharmaceutical Corp. 相关的药物交易

登录后查看更多信息

100 项与 ImmuLogic Pharmaceutical Corp. 相关的转化医学

登录后查看更多信息